Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/14/19
End: 12/18/23
Due: 12/18/24
Phase: N/A
Priority: Normal
Start: 10/07/20
End: 06/12/23
Due: 06/12/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | user2@example.com | None | 2019-03-14 | 2023-12-18 | 2024-12-18 | - | - | 2025-07-14 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | user2@example.com | None | 2020-10-07 | 2023-06-12 | 2024-06-12 | - | - | 2025-07-14 |